ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models

@article{Gardell2007ACP103A5,
  title={ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models},
  author={L. Gardell and K. Vanover and L. Pounds and R. Johnson and Richard A. Barido and Gary Anderson and I. Veinbergs and A. Dyssegaard and P. Brunmark and A. Tabatabaei and R. Davis and M. Brann and U. Hacksell and D. Bonhaus},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2007},
  volume={322},
  pages={862 - 870}
}
Dopamine D2 receptor antagonism contributes to the therapeutic action of antipsychotic drugs (APDs) but also produces undesirable side effects, including extrapyramidal motor deficits, cognitive dulling, and prolactinemia. The introduction of atypical APDs was a significant advancement in the treatment of schizophrenia. Whereas these agents are D2 receptor antagonists, they are also potent 5-hydroxytryptamine (5-HT)2A receptor inverse agonists, a feature that may explain their improved efficacy… Expand
50 Citations
Serotonergic mechanisms as targets for existing and novel antipsychotics.
  • H. Meltzer
  • Medicine
  • Handbook of experimental pharmacology
  • 2012
  • 78
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
  • 48
  • PDF
The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment
  • 104
Clozapine-Induced Locomotor Suppression is Mediated by 5-HT2A Receptors in the Forebrain
  • 48
  • PDF
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease
  • 44
Atypical antipsychotics and inverse agonism at 5-HT2 receptors.
  • 24
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
  • 191
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
  • 182
  • PDF
Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
  • 347
  • Highly Influential
Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.
  • 171
5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade.
  • 93
The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice
  • 85
...
1
2
3
4
5
...